Franklin Resources Inc. Boosts Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,308,546 shares of the company’s stock after purchasing an additional 6,000 shares during the quarter. Franklin Resources Inc.’s holdings in Centessa Pharmaceuticals were worth $38,668,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. FMR LLC boosted its holdings in shares of Centessa Pharmaceuticals by 4.6% in the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after purchasing an additional 129,300 shares during the period. Janus Henderson Group PLC purchased a new position in Centessa Pharmaceuticals during the third quarter worth $20,698,000. Lord Abbett & CO. LLC purchased a new position in Centessa Pharmaceuticals during the third quarter worth $4,305,000. The Manufacturers Life Insurance Company increased its position in Centessa Pharmaceuticals by 88.1% during the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock valued at $4,237,000 after acquiring an additional 124,075 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Centessa Pharmaceuticals by 40.1% in the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after acquiring an additional 54,482 shares during the period. Institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an “overweight” rating and a $38.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $27.71.

Centessa Pharmaceuticals Trading Down 10.6 %

CNTA opened at $11.68 on Friday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock’s fifty day moving average is $16.18 and its two-hundred day moving average is $16.33. The company has a market capitalization of $1.56 billion, a P/E ratio of -7.63 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. Analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karen M. Anderson sold 30,526 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the transaction, the insider now directly owns 54,322 shares of the company’s stock, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,168 shares of company stock valued at $4,309,568. Company insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.